Lilly Advances Sleep Apnea Treatment and Acquires Centessa Pharmaceuticals
Eli Lilly and Company reports Q2 2026 financial results and updates on its clinical pipeline progress and business developments relevant to the sleep medicine industry.
### Financial Results and Pipeline Progress Eli Lilly and Company has released its financial results for the second quarter of 2026, along with updates on its clinical pipeline progress and business developments. The company reported a 48% increase in worldwide revenue, reaching $23.0 billion in Q2 2026. This growth was driven by a 60% increase in volume, primarily due to the company's key products, including Mounjaro and Zepbound. The revenue increase in the US was 33%, reaching $14.4 billion. Lilly also raised its full-year 2026 revenue guidance to between $85 billion and $87 billion, reflecting continued strong revenue performance. ### Advances in Sleep Apnea Treatment Lilly's triple agonist, retatrutide, has demonstrated substantial improvements in obstructive sleep apnea during clinical trials. The treatment has shown potential in addressing obesity and its complications, including weight loss, A1C reduction, knee osteoarthritis pain, and obstructive sleep apnea. ### Acquisition of Centessa Pharmaceuticals Lilly has completed its acquisition of Centessa Pharmaceuticals, aiming to advance treatments for sleep-wake disorders. This acquisition is expected to contribute to the company's efforts in addressing sleep-related issues. ### CEO's Statement David A. Ricks, Lilly chair and CEO, expressed the company's optimism about its future, stating that Lilly's momentum continues, and the company is building for the future. He highlighted the company's next-generation weight-loss medicine, retatrutide, and its complete clinical data package, as well as new manufacturing capacity and exciting new assets entering the pipeline through business development. Lilly's focus on sleep and obesity complications, as well as its commitment to advancing treatments for sleep-wake disorders, positions the company as a leader in the sleep medicine industry. The company's financial results and pipeline progress demonstrate its continued growth and momentum in the market.
